Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics

Summary

GBI Research, the leading business intelligence provider, has released its latest report, “Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics” that provides key data, information and analysis of the major trends and issues in Personalized Medicine Market. The report provides a comprehensive insight into the role of Human Genomics and Proteomics to challenge traditional therapeutics. The report also provides a detailed analysis of market characterization of personalized medicine market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the patent landscape for human genomics and proteomics and provides comprehensive analysis.

Scope

The scope of the report includes:
- Detailed overview of Personalized Medicine Market in pharmaceutical industry along with their use, efficiency and limitation.
- Annualized market data from 2007 and forecast forward till 2016 along with segmentation by geography.
- Key market drivers and restraints shaping the Personalized Medicine Market.
- Competitive landscape analysis with competitive profiling of leading companies.
- Analysis of partnership deals from 2006 to 2010
- Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Develop better strategies for personalized medicine market research by understanding the market dynamics.
- Develop market-entry and market expansion strategies by identifying the key development area
- Understand the factors shaping the Personalized Medicine Market
- For understanding the role of Human Genomics and Proteomics to challenge traditional therapeutics.
- Identify the key players best positioned to take the advantage of the opportunities in the global market.
- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

Table Of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Personalized Medicine Market: Market Overview 10
2.1 Introduction 10
2.1.1 Potential Applications of Personalized Medicine 12
2.2 GBI Research Report Guidance 14
3 Personalized Medicine Market: Drivers and Barriers 15
3.1 Drivers 16
3.1.1 Increase in healthcare costs 16
3.1.2 Advantages over conventional drug discovery methods 16
3.1.3 Patient compliance 16
3.1.4 Early detection of disease 17
3.1.5 Better regulatory norms and validation procedures encourage growth of the personalized medicine market 17
3.2 Barriers 17
3.2.1 Payer Reimbursement Issues 17
3.2.2 Ethical Issues 17
3.2.3 Medical Information Technology 18
3.2.4 Awareness Gap - Lack of Physician Education and Awareness about Novel Technologies 18
3.2.5 Cumbersome and Lengthy Development Procedure Discourages Biomarker Research by the Pharmaceutical Sector 18
4 Personalized Medicine Market - Personalized Therapeutics and Diagnostics 19
4.1 Personalized Therapeutics - Drug Profiles 19
4.1.1 Herceptin (trastuzumab) 19
4.1.2 Erbitux (cetuximab) 24
4.1.3 Gleevec (imatinib) 28
4.1.4 Zyprexa (olazapine) 32
4.1.5 Lipitor (atorvastatin) 35
4.1.6 Celebrex (celecoxib) 39
4.1.7 Tarceva (erlotinib) 42
4.1.8 Rituxan (rituximab) 46
4.1.9 Plavix (clopidogrel bisulfate) 49
4.1.10 Risperdal (risperidone) 51
4.1.11 Vectibix (Panitumumab) 54
4.1.12 Coumadin (Warfarin) 56
4.1.13 Iressa (Gefitinib) 57
4.1.14 Sprycel 59
4.1.15 Camptosar 61
4.2 Companion Diagnostics 62
4.2.1 Selected Companion Diagnostics Employed in Personalized Healthcare 64
4.3 Biomarkers 67
4.3.1 Biomarkers in Cancer Research 68
4.3.2 Market Size and Forecasts 69
4.3.3 Segmentation by Indication 70
5 Personalized Medicine Market: Selected Pipeline Product Profiles 80
5.1 PF-4948568 (Pfizer) 80
5.1.1 Overview 80
5.1.2 Mechanism of Action 80
5.1.3 Clinical Study Details 80
5.2 PF-02341066 + Erlotinib (Pfizer) 81
5.2.1 Overview 81
5.2.2 Mechanism of Action 81
5.2.3 Clinical study details 81
5.3 PF-299804 (Pfizer) 82
5.3.1 Overview 82
5.3.2 Mechanism of action 82
5.3.3 Clinical study details 82
5.4 CEP-701 (Cephalon Inc.) 83
5.4.1 Overview 83
5.4.2 Mechanism of action 83
5.4.3 Clinical study details 84
5.5 TBR-652 (Tobira Therapeutics, Inc) 84
5.5.1 Overview 84
5.5.2 Mechanism of action 84
5.5.3 Clinical study details 85
5.6 Brivanib (Bristol-Myers Squibb) 85
5.6.1 Overview 85
5.6.2 Mechanism of action 85
5.6.3 Clinical study details 86
5.7 Ipilimumab (Bristol-Myers Squibb) 86
5.7.1 Overview 86
5.7.2 Mechanism of Action 86
5.7.3 Clinical Study Details 86
5.8 BiovaxID (Accentia Biopharmaceuticals, Inc.) 87
5.8.1 Overview 87
5.8.2 Mechanism of Action 87
5.8.3 Clinical Study Details 87
6 Personalized Medicine Market: Research Trends in Personalized Medicine 88
7 Personalized Medicine Market: Competitive Landscape 89
7.1 Competitive Profiling 89
7.2 Clarient, Inc. 89
7.2.1 Business Description 89
7.2.2 Pipeline 90
7.2.3 Major Products 90
7.2.4 Partnership and Merger and Acquisition (MandA) Deals 91
7.3 Qiagen N.V. 92
7.3.1 Business Description 92
7.3.2 Pipeline 92
7.3.3 Major Products 92
7.3.4 Partnership and MandA Deals 94
7.4 Laboratory Corporation of America Holdings 96
7.4.1 Business Description 96
7.4.2 Pipeline 96
7.4.3 Major Products 96
7.4.4 Partnership and MandA Deals 97
7.5 bioMerieux S.A. 99
7.5.1 Business Description 99
7.5.2 Pipeline 99
7.5.3 Major Products 99
7.5.4 Partnership and MandA Deals 100
7.5.5 Partnership and MandA Deals 102
7.6 Pfizer 102
7.6.1 Business Overview 102
7.6.2 Partnership and MandA Deals 103
7.7 Eli Lily and Company 104
7.7.1 Business Overview 104
7.7.2 Partnership and MandA deals 105
7.8 Novartis 106
7.8.1 Business Overview 106
7.8.2 Partnership and MandA Deals 107
7.9 F. Hoffman La Roche 108
7.9.1 Business Overview 108
7.9.2 Diagnostics 108
7.9.3 Pharmaceuticals 109
7.9.4 Partnership and MandA Deals 110
7.10 Bristol-Myers Squibb 111
7.10.1 Business Overview 111
7.10.2 Partnership and MandA deals 112
7.11 Merck KGaA 113
7.11.1 Business Overview 113
7.11.2 Partnership and MandA deals 114
7.12 Dako Denmark A/S 116
7.12.1 Business Overview 116
7.12.2 Partnership and MandA deals 116
8 Personalized Medicine Market: Conclusion 117
9 Personalized Medicine Market: Appendix 118
9.1 Market Definitions 118
9.2 Abbreviations 118
9.3 Research Methodology 121
9.3.1 Coverage 122
9.3.2 Secondary Research 122
9.3.3 Primary Research 122
9.3.4 Expert Panel Validation 123
9.4 Contact Us 123
9.5 Disclaimer 123
9.6 Sources 1231.1 List of Tables
Table 1: Herceptin - Snapshot 2010 19
Table 2: Herceptin, Global, Revenues ($m) 2007-2009 23
Table 3: Erbitux - Snapshot 2010 24
Table 4: Erbitux, Global, Revenues ($m) 2007-2009 27
Table 5: Gleevec - Snapshot 2010 28
Table 6: Gleevec, Global, Revenues ($m) 2007-2009 31
Table 7: Zyprexa - Snapshot 2010 32
Table 8: Zyprexa, Global, Revenues ($m) 2007-2009 34
Table 9: Lipitor - Snapshot 2010 35
Table 10: Lipitor, Global, Revenues ($m) 2007-2009 38
Table 11: Celebrex - Snapshot 2010 39
Table 12: Celebrex, Global, Revenues ($m) 2007-2009 41
Table 13: Tarceva - Snapshot 2010 42
Table 14: Tarceva, Global, Revenues ($m) 2007-2009 44
Table 15: Rituxan - Snapshot 2010 46
Table 16: Rituxan, Global, Revenues ($m) 2007-2009 47
Table 17: Rituxan, Global, Revenues 2007-2009 48
Table 18: Plavix - Snapshot 2010 49
Table 19: Plavix, Global, Revenues ($m) 2007-2009 50
Table 20: Risperdal - Snapshot 2010 51
Table 21: Risperdal, Global, Revenues ($m) 2007-2009 53
Table 22: Vectibix - Snapshot 2010 54
Table 23: Coumadin - Snapshot 2010 56
Table 24: Iressa - Snapshot 2010 57
Table 25: Sprycel - Snapshot 2010 59
Table 26: Camptosar - Snapshot 2010 61
Table 27: Personalized Medicine Market, List of Selected Personalized Diagnostics and Therapeutics, 2010* 63
Table 28: Personalized Medicine Market, Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007-2016 69
Table 29: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Breast Cancer Biomarkers Market Revenues ($m), 2007-2016 71
Table 30: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Prostate Cancer Biomarkers Market Revenues ($m), 2007-2016 72
Table 31: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Lung Cancer Biomarkers Market Revenues ($m), 2007-2016 73
Table 32: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Colorectal Cancer Biomarkers Market Revenues ($m), 2007-2016 74
Table 33: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Cervical Cancer Biomarkers Market Revenues ($m), 2007-2016 75
Table 34: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Head and Neck Cancer Biomarkers Market Revenues ($m), 2007-2016 76
Table 35: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Pancreatic Cancer Biomarkers Market Revenues ($m), 2007-2016 77
Table 36: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Ovarian Cancer Biomarkers Market Revenues ($m), 2007-2016 78
Table 37: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Stomach Cancer Biomarkers Market Revenues ($m), 2007-2016 79
Table 38: Personalized Medicine Market, Clarient, Pipeline, August 2010 90
Table 39: Personalized Medicine Market, Clarient, Major MandA Deals, 2005-2010 91
Table 40: Personalized Medicine Market, Clarient, Partnership Deals, 2006-2010 91
Table 41: Personalized Medicine Market, QIAGEN, Pipeline, August 2010 92
Table 42: Personalized Medicine Market, QIAGEN, Major MandA Deals, 2005-2010 94
Table 43: Personalized Medicine Market, QIAGEN, Partnership Deals, 2006-2010 95
Table 44: Personalized Medicine Market, Laboratory Corporation of America Holdings, Pipeline, August 2010 96
Table 45: Personalized Medicine Market, Laboratory Corporation of America Holdings, Major MandA Deals, 2005-2010 97
Table 46: Personalized Medicine Market, Laboratory Corporation of America Holdings, Partnership Deals, 2006-2010 98
Table 47: Personalized Medicine Market, bioMerieux, Pipeline, August 2010 99
Table 48: Personalized Medicine Market, bioMerieux, Major MandA Deals, 2005-2010 100
Table 49: Personalized Medicine Market, bioMerieux, Partnership Deals, 2006-2010 101
Table 47: Personalized Medicine Market, Biomoda, Partnership Deals, 2006-2010 1021.2

List of Figures

Figure 1: Personalized Medicine Market, Potential Applications of Personalized Medicine 12
Figure 2: Personalized Medicine Market, Market Drivers and Restraints, 2010 15
Figure 3: Herceptin, Global, Revenues ($m) 2007-2009 23
Figure 4: Herceptin - SWOT 2010 24
Figure 5: Erbitux, Global, Revenues ($m) 2007-2009 27
Figure 6: Erbitux - SWOT 2010 28
Figure 7: Gleevec, Global, Revenues ($m) 2007-2009 31
Figure 8: Gleevec - SWOT 2010 32
Figure 9: Zyprexa, Global, Revenues ($m) 2007-2009 34
Figure 10: Zyprexa - SWOT 2010 35
Figure 11: Lipitor, Global, Revenues ($m) 2007-2009 38
Figure 12: Lipitor - SWOT 2010 39
Figure 13: Celebrex, Global, Revenues ($m) 2007-2009 41
Figure 14: Celebrex - SWOT 2010 42
Figure 15: Tarceva, Global, Revenues ($m) 2007-2009 44
Figure 16: Tarceva - SWOT 2010 45
Figure 17: Rituxan, Global, Revenues ($m) 2007-2009 47
Figure 18: Rituxan - SWOT 2010 48
Figure 19: Plavix, Global, Revenues ($m) 2007-2009 50
Figure 20: Plavix- SWOT 2010 51
Figure 21: Risperdal, Global, Revenues ($m) 2007-2009 53
Figure 22: Risperdal - SWOT 2010 54
Figure 23: Personalized Medicine Market, Biomarkers in Cancer Research, 2010 68
Figure 24: Personalized Medicine Market, Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007-2016 69
Figure 25: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Market Segmentation by Indication, 2009 70
Figure 26: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Breast Cancer Biomarkers Market Revenues ($m), 2007-2016 71
Figure 27: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Prostate Cancer Biomarkers Market Revenues ($m), 2007-2016 72
Figure 28: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Lung Cancer Biomarkers Market Revenues ($m), 2007-2016 73
Figure 29: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Colorectal Cancer Biomarkers Market Revenues ($m), 2007-2016 74
Figure 30: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Cervical Cancer Biomarkers Market Revenues ($m), 2007-2016 75
Figure 31: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Head and Neck Cancer Biomarkers Market Revenues ($m), 2007-2016 76
Figure 32: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Pancreatic Cancer Biomarkers Market Revenues ($m), 2007-2016 77
Figure 33: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Ovarian Cancer Biomarkers Market Revenues ($m), 2007-2016 78
Figure 34: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Stomach Cancer Biomarkers Market Revenues ($m), 2007-2016 79
Figure 35: Research and Innovation Trends in Personalized Medicine 88
Figure 36: Personalized Medicine Market, Global, Geographic Landscape, 2009 89

Companies mentioned

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Global Next-generation Sequencing Trends

Global Next-generation Sequencing Trends

  • $ 12 500
  • Industry report
  • September 2014
  • by Frost & Sullivan

An End-user Perspective The overall research objective was to capture and analyze global next-generation (NGS) sequencing trends and use. Most researchers outsource NGS technologies; however, in-house ...

 Digital PCR market research PCR reaction  market, target DNA  market,  PCR based diagnostics market, SNP detection market global industry analysis, size, share, growth, trends and forecast, 2013 - 2020

Digital PCR market research PCR reaction market, target DNA market, PCR based diagnostics market, SNP detection market global industry analysis, size, share, growth, trends and forecast, 2013 - 2020

  • $ 7 000
  • Industry report
  • November 2014
  • by Occams

The polymerase chain reaction (PCR) technologies market reached over $6.5 billion at the end of 2013. PCR enables quantification and detection of target DNA. PCR is a valuable tool in diagnosis, clinical ...

Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

This BCC Research report discusses market growth, size and opportunities with respect to applications, geographic region and technologies. Forecast trends and revenue are given through 2019. Major players, ...

Global Metabolomics Market

November 2014 $ 4 950

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.